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Abstract Bariatric surgery is a component of the multimodal
treatment of obesity, which consists of multidisciplinary
evaluation and diagnosis, conservative and surgical treatments,
and lifelong follow-up care. The current guideline extends the
BMI-based spectrum of indications that was previously
proposed (BMI greater than 40 kg/m(2), or greater than 35 kg/
m(2) with secondary diseases) by eliminating age limits, as well
as most of the contraindications. A prerequisite for surgery is
that a structured, conservative weight-loss program has failed or
is considered to be futile. Type 2 diabetes is now considered an
independent indication under clinical study conditions for
patients whose BMI is less than 35 kg/m(2) (metabolic surgery).
The standard laparoscopic techniques are gastric banding,
gastric bypass, sleeve gastrectomy, and biliopancreatic diver-
sion. The choice of procedures is based on knowledge of the
results, long-term effects, complications, and individual circum-
stances. Structured lifelong follow-up should be provided and
should, in particular, prevent metabolic deficiencies.
Keywords Obesity . Bariatric medicine . Individualized
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Introduction
Obesity and its associated diseases are epidemic that represent
a major threat to human health. In the last two decades an
explosive increase in the number of people diagnosed with
diabetes has been observed worldwide and the global figure of
affected individuals is expected to rise from currently 150
million to 300 million in 2025 [1]. The rapidly escalating
number of affected patients at even very young age poses a
tremendous burden on the public health system and a
substantial reinforcement of research activities including
transnational cooperation between scientists from different
disciplines is urgently required to avoid a socio-economic
disaster. For patients with obesity and type 2 diabetes,
bariatric surgery is by far the most effective treatment—it is,
indeed, the only form of treatment that can put patients into
full long-term remission [2]. In this article we will review
and highlight the importance of bariatric surgery as a way to
cut diabetes costs at present. Finally, we will discuss public
health implications. Until a successful non-surgical means
for preventing and reversing obesity is developed, bariatric
surgery appears to be the only intervention that can result in
a sustained reversal of both obesity and type 2 diabetes
mellitus in most patients receiving it. One of the key
recommendations is the need for a multidisciplinary bariatric
team to oversee the ongoing needs of patients after surgery,
as well as to build a weight maintenance program.
The term bariatric medicine refers to gastrointestinal surgical
interventions and subsequent multidisciplinary lifelong follow-
up conducted to produce sustainable weight loss. Bariatric
surgery is a term derived from the Greek words: weight and
treatment. Currently, most obesity clinics and bariatric centers
favor the Lap Band adjustable gastric banding procedure and
the proximal Roux-en-Y Gastric Bypass (Table 1).
Pre-operative patient selection and preparation
The generally accepted indication for gastrointestinal
surgery for weight loss is BMI (body mass index) > 40 or
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BMI > 35 complicated by weight-related co-morbidities
[3]. The clinician should view these parameters as a guide
rather then a rule, as each patient should be assessed on
individual basis (Fig. 1). Before patients undergo bariatric
surgery, it is very important to address their expectations.
Pre-operative and postoperative education must aim to
confront the common patient belief that post-surgical
weight loss will be effortless and that they will achieve
their ‘dream’ weight. Patients need to understand that the
primary goal is to reduce the risks of morbidity and
mortality associated with their pre-surgical weight. Patients
can be asked to describe their weight, ideal weight and
height; actual weight and height can be assessed using a
standard medical scale. After obtaining the surveyed
information, the patient can provide motivational feedback
by addressing three topics of diet and exercise-related
health risks: heart disease (specifically myocardial infarc-
tion), hypertension (and specifically risk for stroke), and
diabetes. Next, patients can elicit questions and provide
short-term realizable goals with respect to diet and exercise
habits. Following the intervention, participants can be
asked whether they would participate in a longitudinal
study of brief motivational intervention. Each patient
engages understanding of the intervention on a scale from
1 to 10, with 1 being the least engaged and 10 being the
most engaged. Patients should understand that undergoing
baritaric surgery is very significant commitment that also
requires dramatic lifestyle changes. In addition, they should
know that for a severely obese person with clinically
significant end-organ damage, the risk of death without
surgery within 1 year is about 10 times that of dying of the
surgery itself.
Biomarkers for predictive diagnostics and preventive
measures
Bariatric surgery is increasingly used as a strategy to reduce
bodyweight and thereby ameliorate risk factors for cardio-
Fig. 1 Individualized approach for the bariatric patient: A flowchart
example system that stratifies in a set of patients, based on a set of
observations. The observations can include physical, biochemical,
histological, genetic, and gene-expression data, among other types of
information. Adjustments can be made to account for the possibility
that observations of several patients may begin at different points in
the progression of their respective disease processes. DM diabetes
mellitus, CVD cardiovascular disease, CVA cerebrovascular accident
Table 1 Description of bariatric surgery procedures
Bariatric technique Description of the procedure
Adjustable Gastric Binding
(AGB)
AGB involves creating of a small upper gastric pouch (15–45 ml in volume), by placing a band around the upper
stomach. The primary aim is to create a mechanical restriction that limits the passage of the food. This enables
the patients to limit portion sizes without feeling undue hunger. Very recently wireless, telemetric adjustable
system has been developed for periodic adjustments of the band.
Roux-en-Y Gastric Bypass
(RYGB)
In a RYGB, the cardia is separated from the remainder of the stomach, creating a small gastric reservoir measuring
approximately 10 ml. This reservoir is then anastomosed to a segment of the proximal jeunum. The small gastric
reservoir restricts food intake and causes degree of malabsoption.
Bileopancreatic Diversion
(BPD)
In a BDP, a subtotal gastrectomy is performed, leaving gastric pouch 200–500 ml in volume. The distal segment
of the small intestine is anastomosed to the gastric remnant and the proximal segment is anastomosed to the
distal ileum 50 cm from the ileocecal valve.
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vascular diseases [4]. On average, patients lose 14–25%
weight after bariatric surgery [5]. Patients who underwent
gastric bypass surgery showed a significant decline in all-
cause mortality as well as coronary artery disease,
diabetes and cancer during 7.1 years follow up [6].
Patients with recently diagnosed type 2 diabetes showed
greater weight loss after gastric banding compared to
conventional therapy (life style advice) as well as a
greater chance of remission of type 2 diabetes [7]. This
effect of bariatric surgery on diabetes is probably due to a
reduction in body fat mass and, in the case of gastric
bypass surgery, changes in gut hormone production such
as Glucagon-Like Peptide-1 (GLP-1), Gastric Inhibitory
Polypeptide (GIP) and grehlin [8]. GLP-1 receptor
agonists induce adiponectin expression while reducing
expression of IL-6 and MCP-1 in 3T3-L1 adipocytes
through the protein kinase A pathway [9]. Finally,
although only limited data is present, plasma GIP levels
may important as seen from in vitro studies showing a
GIP induced reduction in insulin resistance in 3T3-L1
adipocytes through activation of Akt [10]. Although only
limited data is available, the effects of GLP-1 and GIP on
adipocytes may be part of the weight loss independent
effects of gastric bypass surgery on adipose tissue
function. Other beneficial effects of gastric bypass
surgery in comparison to gastric banding may include
a smaller fat mass to fat-free mass ratio with similar
weight loss [11]. Adiponectin levels have been shown
to increase after bariatric surgery in several small
scale studies mainly because of an increase in high
molecular weight adiponectin [12]. After bariatric
surgery, plasma concentrations of Macrophage Inhibitory
Factor (MIF), Plasminogen Activator Inhibitor-1 (PAI-1),
Retinol Binding Protein-4 (RBP-4), Monocyte Chemo-
tactic Protein-1 (MCP-1) and interleukin-18 (IL-18) are
decreased, indicating positive effects on adipose tissue
function [13].
Dual-energy X-ray absorptiometry (DEXA) has been
widely used in not only the diagnosis of osteoporosis but
also the analysis of body composition such as the amount
of bone mineral, adipose tissue, and other soft tissue. With
this technique we can determine the exact amount of
adipose tissue loss following bariatric surgery (Fig. 2).
Bariatric medicine team
A technically proficient team, preferably accredited by a
national certifying organization, provides the necessary
guarantees that patients will receive adequate instructions
before, during and after surgery through the collaboration of a
multidisciplinary team that allows for a greater assurance of
long-term success and helps monitor weight regain.
Surgery
Bariatric surgery appears efficacious compared to standard
care in reducing obesity. Weight losses are greatest with
diversionary procedures, intermediate with diversionary/
restrictive procedures, and lowest with those that are purely
restrictive. Compared with Roux-en-Y gastric bypass,
adjustable gastric banding has lower weight loss efficacy,
but also leads to fewer serious adverse effects. According to
a recent survey, over 90% of bariatric procedures are
performed by laparoscopic approach [14]. The most
commonly performed procedures are Roux-en-Y gastric
bypass (open and laparoscopic), followed by laparoscopic
adjustable gastric banding, and sleeve gastrectomy. Definite
geographic trends are observable in the specific bariatric
procedures being performed. A number of studies have
already demonstrated the efficacy of bariatric surgery for
the treatment of obesity and its co-morbidities, although
there are still only a handful of prospective, controlled
studies with a high level of evidence. Considering the
results derived from a large-scale, prospective, multicenter
studies and a systematic review [15], it can be reasonably
said that bariatric surgery is a safe and feasible intervention
for the treatment of life-threatening morbid obesity under
controlled conditions [16]. Since 2004, the American
Society of Bariatric and Metabolic Surgery administers the
bariatric surgery centers of excellence accredited world-
wide. There are currently 441 centers and 758 surgeons
accredited in the US and Canada. In Europe, accreditation
of bariatric surgery centers of excellence is governed by the
European Accreditation Council for Bariatric Surgery, a
member of the IFSO-European Chapter (International
Federation for the Surgery of Obesity and Metabolic
Disorders-European Chapter). Fifty-four European centers
are currently accredited by this institution.
Nutritionist
Postoperatively, patients experience nutritional, metabolic,
and hormonal changes that have important clinical impli-
cations [17]. While purely restrictive procedures do not
directly lead to deficiencies attributable to malabsoption,
stomal stenosis resulting in markedly reduced food intake
can lead to caloric, protein and other nutritional deficits.
Thus patients should be monitored regularly following
surgery. Menstruating women are vulnerable to developing
iron deficiency anemia, and micronutrient deficiencies such
as vitamin B12, folate and zinc deficiencies are common,
especially following malabsorptive procedures. Bone me-
tabolism is greatly affected, in part due to vitamin D
deficiency, decreased calcium absorption, and secondary
hyperparathyroidism. To prevent deficiencies oral multivi-
tamin preparations should be given to patients undergoing
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bariatric surgery [18]. Women should be placed on calcium
supplement. Patients should be encouraged to consume 60–
120 g of protein daily to maintain lean body mass during
weight loss and long-term maintenance [19]. A change in
dietary orientation by selecting different protein sources
(meat, fish, eggs, legumes with cereals, cheese, tofu…)
combined with powder protein supplements may allow for
achieving the expected protein intake.
Endocrinologist
Diabetes improves acutely in malabsorptive procedures and
in sequence with weight loss in restrictive procedures.
Bariatric surgery can significantly improve glycaemic
control in severely obese patients with Type 2 diabetes. It
is an effective, safe and cost-effective therapy for obese
Type 2 diabetes. Panelists recommend that postoperative
glycemic control should consist of achievement of prepran-
dial blood glucose levels less than 110 mg/dL and
postprandial blood glucose levels no greater than 180 mg/
dL, in order to achieve glycated hemoglobin (HbA1c)
values of 7% or less [20]. Adjusted with the recent IDF
(International Diabetes Federation) recommendations na-
tional guidelines for bariatric surgery need to be developed
for people with Type 2 diabetes and a BMI of 35 kg/m(2) or
more [21]. Polycystic ovarian syndrome improves in nearly
all women with this condition who undergo bariatric
surgery. Testosterone levels in men also improve after
surgery. Consideration of these nutritional, metabolic, and
hormonal changes allows for optimal medical management
following bariatric surgery. Physical activity is a corner-
stone in the medical management of obesity and could be
important for weight loss following bariatric surgery. A
literature search identified 20 publications (19 studies)
reporting physical activity data in relation to bariatric
surgery. Observational evidence of self-reported physical
activity suggests that physical activity increases after
bariatric surgery and that physical activity is associated
with surgically induced weight loss [22].
Cardiologist
Weight loss by means of caloric restriction or surgery
results in favorable hemodynamic changes referred to as
“reverse remodeling”. Regression of left ventricular (LV)
mass and chamber size has been shown universally.
However, some studies have failed to reveal improvement
in diastolic function possibly because of confounders such
as nutritional deficiency that may occur after weight loss
surgery. Some evidence seems to suggest that the greatest
regression of LV mass and LV hypertrophy may occur when
weight loss is combined with beta-adrenergic blocker
therapy (in those who have an indication for the drug)
when compared with other antihypertensive drugs versus
weight loss alone [23].
Psychologist
Although obesity is considered to be a medical condition,
psychosocial variables influence its development, course,
and treatment. To date, obesity research focuses heavily on
the associated physical problems and the identification of
effective treatments. While an array of behavioral, pharma-
cological and surgical treatments has been developed, their
Fig. 2 The two classes of sur-
gical procedures most common-
ly used to produce weight loss
are: a) gastric restriction
(adjustable gastric binding) and
b) malabsorbtion (Roux-en-Y
gastric bypass and bilopancre-
atic diversion). Among variety
of biomarkers used to monitor
weight loss most clinically
proven are: serum adiponectin
and whole body DEXA scan.
AGB Adjustable Gastric Bind-
ing, RYGB Roux-en-Y Gastric
Bypass, BDP Bilopancreatic
Diversion
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ability to demonstrate long-term weight losses is not
convincing. Thus, there has been a shift towards the
identification of psychological and social factors that may
assist in the prediction of successful treatments, most
notably in the surgical treatment of obesity. As a result,
less emphasis has been placed on post-treatment psychoso-
cial influences. As the treatment of obesity becomes
increasing multidimensional, the need for attention to
psychosocial factors and the involvement of mental health
providers increases. For the allied or mental health provider,
a comprehensive understanding of obesity’s physical,
psychological and social basis is vital to ensure proper
assessment or treatment, as it is warranted. More information
is needed regarding factors that interfere with successful
outcomes and mechanisms of optimal follow-up for bariatric
surgery patients to prevent and detect post-operative medical,
psychological and social difficulties [24].
Conclusion and outlook
According to a report (Shedding the pounds “Obesity
management, NICE guidance and bariatric surgery in
England”) released by the UK Office of Health Economics,
an independent research body, a big increase in bariatric
surgery among people who meet the current criteria would
pay for itself in 1 year, by enabling many of them to return
to paid employment [25]. According to this report, around
one million people in England currently meet the criteria
for bariatric surgery recommended by the National Institute
for Health and Clinical Excellence, of whom only 5% to
10% may actually be eligible for surgery. If just 5% of
eligible patients were to receive bariatric surgery the net
gain to the UK economy within 3 years could be £382 m.
Critics of the report point out that it was commissioned by
the Royal College of Surgeons of England together with the
National Obesity Forum and Allergan and Covidien,
companies that make products for obesity surgery. Critics
also note that this money would be better spent on
prevention efforts (though they don’t present any data
showing that such efforts will actually prevent current costs
of people who are already obese). John Ashton, the
chairman of the UK Public Health Association, is quoted
in the British Medical Journal as raising the issue of
opportunity cost of spending money on surgery that is then
not available for other health services and conditions that
are not preventable. This is a moot argument as, irrespective
of whether or not obesity is preventable, not spending the
money on surgery for those who already have the problem,
will just mean spending more money on managing their
many complications, e.g. type 2 diabetes mellitus.
In addition, the International Diabetes Federation (IDF)
published in April 2011 Executive Summary pointing out
that “Bariatric surgery is an appropriate treatment for
people with type 2 diabetes and obesity not achieving
recommended treatment targets with medical therapies,
especially when there are other major co-morbidities” [21].
The Endocrine Society recently released a clinical
practice guideline that highlights the need for endocrine
and nutritional management of patients after bariatric
surgery, including those with diabetes [26]. Given the large
number of people undergoing bariatric surgery, it is
important for endocrinologists and primary care physicians
to be knowledgeable about the postoperative care of these
patients. The patients have a risk for weight regain if they
do not participate in ongoing dietary and behavioral care in
the long term. One of the key recommendations in the
guideline is the need for a multidisciplinary team to oversee
the ongoing dietary needs of patients after surgery. This
should not be done by the surgeons alone. The team should
include psychologists, nutritionists, endocrinologists, etc. to
evaluate patients, as many patients present with different
problems.
Emerging bariatric techniques are: implantable gastric
stimulator and VBLOC therapy with surgically implanted
device that delivers high-frequency, low energy electrical
signals. It is thought that weight loss is mediated by
interruption of hunger signals that travel via the vagus
nerve to the brain, though the exact mechanism of action
has yet to be elucidated.
With the growing interest in bariatric surgery not only are
primary care practitioners face with an increasing number of
requests for referral to surgery but they are called upon to look
after an ever increasing number of patients who have
undergone bariatric surgery [27]. In this article we provide
a succinct overview of how multidisciplinary team should
prepare the selection criteria for surgery, types of surgery,
risks and benefits, long-term complications, as well as
monitoring and management issue relevant to the care of
these complex patients. While it is impossible to summarize
the vast and rapidly expanding literature on bariatric surgery
in a short article, we do hope that this paper will provide a
useful resource to anyone seeking a quick state-of-the-art
overview of bariatric medicine.
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